| Drug General Information |
| Drug ID |
D0W4OZ
|
| Former ID |
DPR000051
|
| Drug Name |
GG-8573
|
| Indication |
Gallstone prophylaxis; Obesity [ICD9: 278; ICD10:E66]
|
Preclinical |
[1]
|
|---|
| Company |
GSK
|
| Target and Pathway |
| Target(s) |
Cholecystokinin receptor type A |
Target Info |
Agonist |
[1]
|
|---|
| Gastrin/cholecystokinin type B receptor |
Target Info |
Antagonist |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Insulin secretion
|
|
Pancreatic secretionhsa04020:Calcium signaling pathway
|
|
Gastric acid secretion
|
|
PANTHER Pathway
|
CCKR signaling map ST
|
|
PathWhiz Pathway
|
Gastric Acid Production
|
|
Reactome
|
Peptide ligand-binding receptors
|
|
G alpha (q) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (q) signalling events
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Peptide GPCRs
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
Secretion of Hydrochloric Acid in Parietal Cells
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. |
|---|
